MedTrace Logo

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

NCT05330858 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-05-09

No results posted yet for this study

Summary

This is a single-center, in-house, open-label, crossover study in 15 healthy participants.

Conditions

  • Pharmacokinetics

Interventions

DRUG

ESK-001

Oral tablet or liquid

DRUG

Rabeprazole

Oral Tablet

Sponsors & Collaborators

  • Alumis Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-17
Primary Completion
2022-06-30
Completion
2022-09-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05330858 on ClinicalTrials.gov